Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation
Autore:
Przepiorka, D; Devine, SM; Fay, JW; Uberti, JP; Wingard, JR;
Indirizzi:
Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 Gene Therapy, Houston, TX 77030 USA Univ Illinois, Med Ctr, Chicago, IL USA Univ Illinois Chicago IL USAUniv Illinois, Med Ctr, Chicago, IL USA Baylor Univ, Med Ctr, Dallas, TX USA Baylor Univ Dallas TX USABaylor Univ, Med Ctr, Dallas, TX USA Univ Michigan, Med Ctr, Ann Arbor, MI USA Univ Michigan Ann Arbor MI USAUniv Michigan, Med Ctr, Ann Arbor, MI USA Univ Florida, Hlth Sci Ctr, Gainesville, FL USA Univ Florida Gainesville FL USA orida, Hlth Sci Ctr, Gainesville, FL USA
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 10, volume: 24, anno: 1999,
pagine: 1053 - 1056
SICI:
0268-3369(199911)24:10<1053:PCITUO>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
VERSUS-HOST DISEASE; METHOTREXATE; FK506; PREVENTION; CYCLOSPORINE; PROPHYLAXIS;
Keywords:
tacrolimus; graft-versus-host disease; allogeneic marrow transplantation; therapeutic drug monitoring;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Przepiorka, D Baylor Coll Med, Ctr Cell & Gene Therapy, 6595 Fannin St,M964, Houston, TX77030 USA Baylor Coll Med 6595 Fannin St,M964 Houston TX USA 77030 USA
Citazione:
D. Przepiorka et al., "Practical considerations in the use of tacrolimus for allogeneic marrow transplantation", BONE MAR TR, 24(10), 1999, pp. 1053-1056

Abstract

Tacrolimus has been shown to be more effective than cyclosporine for prevention of acute graft-versus-host disease (GVHD), A number of transplant centers have therefore adopted tacrolimus as standard prophylaxis, but with additional experience, current management of tacrolimus differs from that in the clinical studies. Therefore, a consensus conference was convened to assess the current practices. For prevention of GVHD, conference participants recommended administering tacrolimus at 0.03 mg/kg/day (by lean body weight) i.v. by continuous infusion from day -1 or -2 pretransplant, with day -2 used especially for pediatric patients. Therapeutic drug monitoring was considered essential in the management of patients on tacrolimus, The consensus target range for the whole blood concentration was 10-20 ng/ml, Doses were modified for blood levels outside the target range or for nephrotoxicity,and tacrolimus was discontinued for intolerable tremor, hemolytic uremic syndrome, leukoencephalopathy or other serious toxicity. Tacrolimus was employed most frequently in combination with minimethotrexate (5 mg/m(2) i.v. days 1, 3, 6 and 11), Tapering was individualized according to center practice. No patient category was excluded from use of tacrolimus based on age, extent of disease, patient-donor histocompatibility or stem cell source. Tacrolimus was also used successfully for treatment of chronic GVHD, The responsiveness of steroid-refractory acute GVHD was marginal, so it was deemed more prudent to use tacrolimus for prophylaxis instead.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 19:40:26